Gemcitabine and carboplatin for pretreated metastatic breast cancer: the predictive value of immunohistochemically defined subtypes

No abstract is available for this paper.

• Publication year

  2013

• Venue

  International Journal of Clinical Oncology

• Publication date

  2013-04-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s10147-012-0384-xPMID 22350024
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Strategies for subtypes—dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011

  2011cited by this paper
• Cancer Statistics, 2009

  2009cited by this paper
• Treatment options for breast cancer resistant to anthracycline and taxane.

  2009cited by this paper
• Presenting Features of Breast Cancer Differ by Molecular Subtype

  2009cited by this paper
• Breast Cancer Subtypes Based on ER/PR and Her2 Expression: Comparison of Clinicopathologic Features and Survival

  2009cited by this paper
• Concordance of clinical and molecular breast cancer subtyping in the context of preoperative chemotherapy response

  2009cited by this paper
• Ki67 Index, HER2 Status, and Prognosis of Patients With Luminal B Breast Cancer

  2009cited by this paper
• The prognostic significance of Ki67 before and after neoadjuvant chemotherapy in breast cancer

  2009cited by this paper
• Relationship between oestrogen receptor status and proliferation in predicting response and long-term outcome to neoadjuvant chemotherapy for breast cancer

  2009cited by this paper
• Breast cancer subtypes and response to docetaxel in node-positive breast cancer: use of an immunohistochemical definition in the BCIRG 001 trial.

  2009cited by this paper
• Single agent versus combination chemotherapy for metastatic breast cancer.

  2009cited by this paper
• Phase II trial of gemcitabine/carboplatin (plus trastuzumab in HER2-positive disease) in patients with metastatic breast cancer.

  2008cited by this paper
• Current status of prognostic profiling in breast cancer.

  2008cited by this paper
• Multiple-treatments meta-analysis of chemotherapy and targeted therapies in advanced breast cancer.

  2008cited by this paper
• Biological Processes Associated with Breast Cancer Clinical Outcome Depend on the Molecular Subtypes

  2008cited by this paper
• Gemcitabine and Carboplatin in Intensively Pretreated Patients with Metastatic Breast Cancer

  2008cited by this paper
• Overview of resistance to systemic therapy in patients with breast cancer.

  2007cited by this paper
• Gene expression analysis for predicting gemcitabine sensitivity in pancreatic cancer patients.

  2007cited by this paper
• Gene expression signature predicting pathologic complete response with gemcitabine, epirubicin, and docetaxel in primary breast cancer.

  2006cited by this paper
• American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer.

  2006cited by this paper
• Chemotherapy: what progress in the last 5 years?

  2005cited by this paper
• Role of transforming growth factor Beta in human cancer.

  2005cited by this paper
• Breast Cancer Molecular Subtypes Respond Differently to Preoperative Chemotherapy

  2005cited by this paper
• Single agent versus combination chemotherapy for metastatic breast cancer.

  2005cited by this paper
• Novel association with gemcitabine and docetaxel as salvage chemotherapy in metastatic breast cancer previously treated with anthracyclines: results of a multicenter phase II study.

  2004cited by this paper
• Facts and controversies in systemic treatment of metastatic breast cancer.

  2004cited by this paper
• Gemcitabine and platinum combinations in patients with breast cancer previously treated with anthracyclines and/or taxanes.

  2004cited by this paper
• Gemcitabine plus carboplatin combination therapy as second-line treatment in patients with relapsed breast cancer.

  2004cited by this paper
• Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications

  2001cited by this paper
• Molecular portraits of human breast tumours

  2000cited by this paper
• Optimal two-stage designs for phase II clinical trials.

  1989cited by this paper
• Cancer statistics

  1989cited by this paper

• Efficacy analysis of neoadjuvant chemotherapy regimens in patients with HER2/neunegative locally advanced breast cancer: A nonrandomized comparative study

  2025cites this paper
• Unravelling Eribulin’s role in metastatic breast cancer: evaluating benefits for both triple negative and non-triple negative patients in real-world scenarios in resource-constrained settings

  2024cites this paper
• Progesterone receptor expression contributes to gemcitabine resistance at higher ECM stiffness in breast cancer cell lines

  2022cites this paper
• A Retrospective Study of Gemcitabine and Carboplatin With or Without Intravenous Vitamin C on Patients With Advanced Triple-Negative Breast Cancer

  2020cites this paper
• A phase 2 open-label study of carboplatin in combination with gemcitabine as a dose-dense schedule in patients with locally advanced or metastatic breast cancer that are resistant to anthracyclines and taxanes

  2020cites this paper
• Breast Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology.

  2020cites this paper
• NCCN CLINICAL PRACTICE GUIDELINES IN ONCOLOGY

  2019cites this paper
• Single‐Agent Gemcitabine vs. Carboplatin‐Gemcitabine in Advanced Breast Cancer: A Retrospective Comparison of Efficacy and Safety Profiles

  2019cites this paper
• Palliative treatment with carboplatin as late line therapy to patients with metastatic breast cancer

  2018cites this paper
• Clinical and Genomic Implications of Luminal and Basal Subtypes Across Carcinomas

  2018cites this paper
• A Bumpy Course: Nodules Along a Mastectomy Scar.

  2017cites this paper
• Ixabepilone and Carboplatin for Hormone Receptor Positive/HER2‐neu Negative and Triple Negative Metastatic Breast Cancer

  2017cites this paper
• Hohe Heilungschancen bei Brustkrebs

  2016cites this paper
• NANOTECHNOLOGY APPROACH FOR TARGETED TREATMENT OF TRIPLE NEGATIVE BREAST CANCER

  2016cites this paper
• Durable Clinical Benefit of Pertuzumab in a Young Patient with BRCA2 Mutation and HER2-Overexpressing Breast Cancer Involving the Brain

  2016cites this paper
• Temporally sequenced anticancer drugs overcome adaptive resistance by targeting a vulnerable chemotherapy-induced phenotypic transition

  2015cites this paper
• Gemcitabine and Carboplatin in Patients with Refractory or Progressive Metastatic Breast Cancer after Treatment

  2014cites this paper